Nuclear Imaging Devices Market - By Product Type (Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), Planar Scintigraphy), By Application (Oncology, Cardiology, Neurology), By End User (Hospitals, Diagnostic Imaging Centers) – Global Forecast to 2032

Nuclear Imaging Devices Market Size

Nuclear Imaging Devices Market size was valued at over USD 3 billion in 2022 and is anticipated to grow at a CAGR of over 4.9% between 2023 and 2032.  Growing demand for non-invasive diagnostic tools along with rising emphasis on personalized medicine, thereby impelling the demand for nuclear imaging devices industry.
 

The industry refers to the segment of the medical imaging industry that involves the use of radioactive tracers and specialized imaging equipment to visualize and assess the physiological and metabolic functions of organs and tissues within the human body. Nuclear imaging techniques utilize radiopharmaceuticals that emit gamma rays or positrons, which are detected by dedicated imaging devices to create images and provide functional information. The market is driven by several factors such as the increasing prevalence of chronic diseases, technological advancements in imaging systems and radiopharmaceuticals.
 

Rapid technological advancements in nuclear imaging offering better imaging capabilities, improve patient outcomes will drive overall growth of the industry. Also, emergence of hybrid imaging systems with combination of the functional imaging capabilities of nuclear imaging modalities like SPECT and PET with anatomical imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI). Hybrid systems, such as PET/CT and SPECT/CT provide comprehensive and precise imaging by merging functional and structural information and allows improved diagnostic accuracy, better localization of abnormalities and enhanced patient management. In addition, several market players are emphasizing on research and development activities for the development of novel nuclear imaging devices will accelerate industry expansion.
 

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the nuclear imaging devices market. Due to the prioritization of resources and efforts towards managing and containing the spread of the virus, the demand for non-essential medical procedures experienced a temporary decline. Many healthcare facilities postponed or rescheduled elective imaging procedures to minimize the risk of virus transmission and conserve resources for COVID-19 patients. However, several governments categorized nuclear imaging procedure as essential medical procedure for detection of COVID-19 thereby experienced significant product demand. The increased need for accurate diagnosis, treatment planning, and disease monitoring, coupled with advancements in technology and emphasis on personalized medicine, are some of the factors accelerated market demand to some extent.
 

Nuclear Imaging Devices Market Trends

Growing several chronic disease burdens across the globe is major factor driving overall industry growth.  Surging prevalence rate of several diseases such as cardiovascular disorders, cancer, neurologic conditions, and metabolic disorders requiring advanced diagnostic tools for accurate assessment and management. Nuclear imaging plays a crucial role in the diagnosis, staging, and monitoring of these diseases, providing valuable functional and metabolic information. With the rise in chronic diseases, the demand for nuclear imaging devices is anticipated to witness unprecedented growth opportunities. Moreover, rising preference for nuclear imaging such as SPECT and PET by healthcare providers to obtain detailed insights into disease progression, treatment response, and patient outcomes.
 

Nuclear Imaging Devices Market Analysis

Based on product type, the nuclear imaging devices market is segmented into single photon emission computed tomography (SPECT), positron emission tomography (PET), planar scintigraphy and others. Further, SPECT is segregated into standalone SPECT and hybrid SPECT/CT. PET is subdivided into standalone PET and hybrid PET/CT. SPECT segment is anticipated to exhibit enormous growth over the estimated period. Growing development of hybrid SPECT/CT systems, which combine the functional information provided by SPECT with the anatomical details obtained from CT scans. This integration allows for more precise localization and characterization of abnormalities and improved diagnostic accuracy will foster segmental growth. Moreover, utilization of advanced reconstruction algorithms, such as iterative reconstruction techniques to enhance image quality, reduce noise and improve quantitative accuracy in SPECT imaging.

The nuclear imaging devices market by application is segmented into oncology, cardiology, neurology, and others. The oncology segment was accounted for more than 49% market share in the year 2022. Increasing usage of positron emission tomography imaging for diagnosis, treatment planning, and response assessment of various cancers will fortify segment revenue size. Furthermore, advancements in image reconstruction algorithms and quantitative analysis techniques are enhancing the accuracy and reliability of oncologic imaging, aiding in treatment selection and personalized medicine approaches. With the rising incidence rate of cancer globally is poised to drive overall business growth.

Nuclear imaging devices market by end-use is subdivided into hospitals, diagnostic imaging centers, and others. The hospitals segment garnered notable market share and accounted for more than USD 1 billion revenue size in 2022. Integration of nuclear imaging devices within the hospital infrastructure to allow seamless workflow and streamlined patient care will accelerate the segmental growth potential. Hospitals are investing in advanced nuclear imaging systems such as SPECT and PET scanners to enhance their diagnostic capabilities and provide comprehensive imaging services is anticipated to boost product demand.
 

Additionally, growing emphasis on multidisciplinary collaboration within hospitals, where nuclear medicine departments work closely with other specialties such as oncology, cardiology, and neurology to facilitate integrated patient care. This collaborative approach ensures optimal utilization of nuclear imaging devices and enables more accurate diagnosis, treatment planning, and monitoring of patients is expected to bolster segmental growth potential.

U.S. nuclear imaging devices market accounted for more than USD 950 million in 2022 and will grow lucratively to reach more than USD 1,505 million by 2032. Increasing prevalence of chronic diseases, technological advancements, the shift towards personalized medicine and the integration of remote monitoring and telehealth solutions are some of the few aspects accelerating overall market growth in the U.S. Increasing prevalence of chronic diseases such as cardiovascular disorders, cancer, and neurological conditions in the U.S. will boost industry revenue size. Additionally, technological advancements in nuclear imaging such as hybrid imaging systems with improved image reconstruction algorithms are further propelling the market. Further, the region's high healthcare spending on health care management and rising disposable income will propel the expansion of the U.S. market expansion.

Nuclear Imaging Devices Market Share

Some of the notable key industry players operating in the nuclear imaging devices market include

• DIGIRAD Corporation
• Neusoft Corporation
• CANON MEDICAL SYSTEMS CORPORATION
• SurgicEye GmbH
• CMR Naviscan.
• Absolute Imaging Inc.
• Bartec Technologies Ltd.
• BCL X-Ray Canada Inc.
• TTG Imaging Solutions, LLC.
• Lucerno Dynamics LLC.
• Berthold Technologies GmbH & Co.KG
• Incom Inc.
• Koninklijke Philips N.V.
• GE Healthcare
• Siemens Healthineers AG

These market participants are implementing several growth strategies such as partnerships, collaborations, acquisitions & mergers, and new product development & launches to strengthen product offerings as well as gain a competitive edge over others. ss

Nuclear Imaging Devices Industry News:

• In October 2022, GE Healthcare introduced Omni Legend, an innovative all-digital PET-CT system that offers higher sensitivity, faster procedural time, improved operational efficiency and enhanced patient outcome. This product launch offered competitive edge to the company in the nuclear imaging devices industry.
   
• In June 2022, Siemens Healthineers AG received clearance for its Symbia Pro.specta by the Food and Drug Administration. Symbia Pro.specta is an all-purpose SPECT/CT system with integration of advanced CT and SPECT imaging technologies. Such product approvals enhanced company’s operational capabilities as well as growth opportunities in the significant market.
   

Nuclear imaging devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product Type

• Single Photon Emission Computed Tomography (SPECT)
• Standalone SPECT
• Hybrid SPECT/CT

• Positron Emission Tomography (PET)
• Standalone PET
• Hybrid PET/CT
• Planar Scintigraphy
• Others

By End-use

• Oncology
• Neurology
• Cardiology
• Others

By End User (USD Million)

• Hospitals
• Diagnostic Imaging Centers
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Switzerland
  • The Netherlands
  • Poland
  • Sweden
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • New Zealand
  • Indonesia
  • Thailand
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Iran